In the majority of treated patients, the tumor lesions and PSA levels were reduced after multiple cycles of 177Lu-PSMA-617 therapy4, however, complete remission remained rare and some patients still showed progressive disease after several therapy cycles3,5. This evidence concerns the gene FOLH1 and neoplasm.